Anthem Biosciences gets SEBI's approval to raise funds via IPO

09 Apr 2025 Evaluate

Anthem Biosciences has received markets regulator Securities and Exchange Board of India’s (SEBI's) clearance to raise funds through initial public offering (IPO). The proposed IPO is entirely an offer for sale (OFS) worth Rs 3,395 crore by promoters, investors and other selling shareholders. 

Since the IPO is entirely an OFS, the company will not receive any funds from the issue and the proceeds will go to the selling shareholder. JM Financial, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) are the book-running lead managers for the issue. 

Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem's business also manufactures and sale of specialty ingredients. It also manufactures and sells complex specialised fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes, peptides, and biosimilars. 


Anthem Biosciences Share Price

595.15 0.55 (0.09%)
30-Jan-2026 12:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1591.00
Dr. Reddys Lab 1219.20
Cipla 1323.70
Zydus Lifesciences 887.20
Lupin 2141.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×